58482-93-2

Usage

Uses

Used in Organic Synthesis:
N-T-BUTYLGLYCINE SODIUM SALT is used as an intermediate in organic synthesis for its ability to facilitate the formation of complex organic molecules, contributing to the development of new chemical entities.
Used in Pharmaceutical Manufacturing:
In the pharmaceutical industry, N-T-BUTYLGLYCINE SODIUM SALT is utilized as a building block in the production of various pharmaceutical products, enhancing the synthesis of drugs and improving their efficacy.
Used as a Buffer:
N-T-BUTYLGLYCINE SODIUM SALT is used as a buffer to control the pH of solutions, ensuring stability and consistency in chemical reactions and processes that require a specific pH environment.
Used as a Chiral Selector in Chromatography:
In analytical chemistry, N-T-BUTYLGLYCINE SODIUM SALT is employed as a chiral selector in chromatography, aiding in the separation of enantiomers and improving the purity and specificity of chemical analyses.
Used in Therapeutic Applications:
N-T-BUTYLGLYCINE SODIUM SALT has been studied for its potential as a therapeutic agent, with ongoing research exploring its use in treating various diseases and disorders, highlighting its potential impact on medicine.

InChI:InChI=1/C6H13NO2.Na/c1-6(2,3)7-4-5(8)9;/h7H,4H2,1-3H3,(H,8,9);/q;+1/p-1

Upstream product

• 762-84-5 N-tert-butylacetamide 
• 105-36-2 ethyl bromoacetate 
• 75-64-9 tert-butylamine 
• 14610-37-8 N-methyl-tert-butylamine 
• 2504-18-9 tert-butyl-methyl-nitroso-amine 
• 107-16-4 glycolonitrile 
• 37885-76-0 ethyl 2-(tert-butylamino)acetate 
• 6939-24-8 N-nitroso-N-(t-butyl)glycine 

Downstream Products

• 6939-24-8 N-nitroso-N-(t-butyl)glycine 
• 1310682-46-2 N-(3,4-dichlorophenyl)-N'-(1-tert-butyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)guanidine 
• 1310682-49-5 N-(tert-butoxycarbonyl)-N'-(3,4-dichlorophenyl)-N''-(1-tert-butyl-4-oxo-4,5-dihydro-1H-imidazol-2-yl)guanidine 
• 220620-09-7 tigecycline 
• 85916-13-8 tert-butyl iminodiacetate 
• 62965-35-9 N-tert-butyloxycarbonyl-L-tert-leucine 
• 6939-25-9 3-(t-butyl)sydnone 

Relevant academic research and scientific papers

2-GUANIDINO-4-OXO-IMIDAZOLINE DERIVATIVES AS ANTIMALARIAL AGENTS, SYNTHESIS AND METHODS OF USE THEREOF

The present invention relates to new 2-guanidino-4-oxo-imidazoline derivatives (deoxo-IZ), methods of making these compounds, compositions containing the same, and methods of using the same to prevent, treat, or inhibit malaria in a subject.

Synthesis and antimalarial activity of 2-guanidino-4-oxoimidazoline derivatives

A series of 2-guanidino-4-oxoimidazoline (deoxo-IZ) derivatives was prepared and showed potent antimalarial activities in rodent and Rhesus models. Compound 8e, the most potent analogues of this series, is the first non-8-aminoqinoline antimalarial that demonstrated radical curative activity in non-human primate by oral route and showed causal prophylactic activity comparable to that of the commonly used clinical drugs in Rhesus monkeys infected with sporozoites of Plasmodium cynomolgi. The metabolic stability and metabolites profile indicated that the new deoxo-IZ derivatives (8) may act as prodrugs of the corresponding IZ (1 and 2) derivatives.

PROCESS FOR PRODUCTION OF PYRROLIDINE COMPOUNDS

A process for the production of compounds represented by the general formula (3) or salts thereof: (3) which comprises reacting a compound represented by the general formula (1): (1) with a compound represented by the general formula (2) or a salt thereof

METHOD OF SEARCHING SUBSTANE HAVING ANTIDIABETIC ACTIVITY

The present invention provides a screening method of a substance which inhibits binding of a condensed purine derivative to a pancreatic β cell or a treated product of the cell, a substance which inhibits binding of a condensed purine derivative to a protein capable of the condensed purine derivative, and a substance which inhibits the expression or enzymatic activity of a protein capable of a condensed purine derivative, which comprises using the condensed purine derivative and a pancreatic β cell or a treated product of the cell or a protein capable of binding to the condensed purine derivative.

Process for producing beta-1, 3-n-acetylglucosamine transferase and n-acetylglucosamine- containing composite saccharide

The present invention can provide a process for producing a protein having β1,3-N-acetylglucosaminyltransferase activity using a transformant comprising a DNA encoding a protein having β1,3-N-acetylglucosaminyltransferase activity derived from a microorganism belonging to the genus Pasteurella and a process for producing an N-acetylglucosamine-containing complex carbohydrate using a transformant capable of producing a protein having β1,3-N-acetylglucosaminyltransferase activity derived from a microorganism.

Process for producing alpha 2,3/ alpha 2,8-sialyltransferase and sialic acid-containing complex sugar

The present invention can provide a process for producing a protein having α2,3/α2,8-sialyltransferase activity using a transformant comprising a DNA encoding a protein having α2,3/α2,8-sialyltransferase activity derived from a microorganism belonging to the genus Pasteurella and a process for producing a sialic acid-containing complex carbohydrate using a transformant capable of producing a protein having α2,3/α2,8-sialyltransferase activity derived from a microorganism.

Beta1, 3-galactose transferase and dna encoding the enzyme

The present invention provides a protein having β1,3-galactosyltransferase activity, a DNA encoding the protein, a transformant comprising the DNA, a process for producing the protein using the transformant, and a process for producing a galactose-containing complex carbohydrate using the transformant.

Process for producing alpha1,4-galactosyltransferase and galactose-containing complex sugar

The present invention can provide a process for producing a protein having α1.4-galactosyltransferase activity using a transformant comprising a DNA encoding a protein having α1.4-galactosyltransferase activity derived from a microorganism belonging to the genus Pasteurella and a process for producing a galactose-containing complex carbohydrate using a transformant capable of producing a protein having α1,4-galactosyltransferase activity derived from a microorganism.

Human CDR-grafted antibody and antibody fragment thereof

A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.